These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30461299)

  • 21. The Role of Sex Hormones in Multiple Sclerosis.
    Avila M; Bansal A; Culberson J; Peiris AN
    Eur Neurol; 2018; 80(1-2):93-99. PubMed ID: 30343306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of autoantibodies associated with myelin damage in multiple sclerosis.
    Genain CP; Cannella B; Hauser SL; Raine CS
    Nat Med; 1999 Feb; 5(2):170-5. PubMed ID: 9930864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Demyelination and autoimmunity].
    Lebar R
    Pathol Biol (Paris); 1987 Mar; 35(3):275-83. PubMed ID: 3295694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis.
    Reale M; Sanchez-Ramon S
    Curr Med Chem; 2017; 24(2):176-192. PubMed ID: 27881065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural products: Potential therapeutic agents in multiple sclerosis.
    Yu S; Liu M; Hu K
    Int Immunopharmacol; 2019 Feb; 67():87-97. PubMed ID: 30537635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myelin Basic Protein Citrullination, a Hallmark of Central Nervous System Demyelination, Assessed by Novel Monoclonal Antibodies in Prion Diseases.
    Jang B; Jeon YC; Shin HY; Lee YJ; Kim H; Kondo Y; Ishigami A; Kim YS; Choi EK
    Mol Neurobiol; 2018 Apr; 55(4):3172-3184. PubMed ID: 28470584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in demyelinating disease.
    Yamamoto S; Yamashina K; Ishikawa M; Gotoh M; Yagishita S; Iwasa K; Maruyama K; Murakami-Murofushi K; Yoshikawa K
    J Neuroinflammation; 2017 Jul; 14(1):142. PubMed ID: 28732510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis.
    Hartung HP; Kieseier BC; Hemmer B
    J Neurol; 2005 Nov; 252 Suppl 5():v30-7. PubMed ID: 16254700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Restoration of FcRgamma/Fyn signaling repairs central nervous system demyelination.
    Seiwa C; Yamamoto M; Tanaka K; Fukutake M; Ueki T; Takeda S; Sakai R; Ishige A; Watanabe K; Akita M; Yagi T; Tanaka K; Asou H
    J Neurosci Res; 2007 Apr; 85(5):954-66. PubMed ID: 17290413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Demyelinating antibodies in multiple sclerosis.
    Wolfgram F; Duquette P
    Neurology; 1976 Jun; 26(6 PT 2):68-9. PubMed ID: 944899
    [No Abstract]   [Full Text] [Related]  

  • 31. Multiple Sclerosis: Basic and Clinical.
    Buzzard K; Chan WH; Kilpatrick T; Murray S
    Adv Neurobiol; 2017; 15():211-252. PubMed ID: 28674983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease.
    Schluesener HJ; Sobel RA; Linington C; Weiner HL
    J Immunol; 1987 Dec; 139(12):4016-21. PubMed ID: 3500978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Myelin antibodies].
    Aarli JA
    Tidsskr Nor Laegeforen; 1975 Sep; 95(26):1485-9. PubMed ID: 1179363
    [No Abstract]   [Full Text] [Related]  

  • 34. Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis.
    McFarland HI; Lobito AA; Johnson MM; Nyswaner JT; Frank JA; Palardy GR; Tresser N; Genain CP; Mueller JP; Matis LA; Lenardo MJ
    J Immunol; 1999 Feb; 162(4):2384-90. PubMed ID: 9973519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological aspects of demyelinating diseases.
    Martin R; McFarland HF; McFarlin DE
    Annu Rev Immunol; 1992; 10():153-87. PubMed ID: 1375472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
    Savarin C; Bergmann CC; Gaignage M; Stohlman SA
    J Neuroinflammation; 2015 Nov; 12():207. PubMed ID: 26559484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pathogenesis of multiple sclerosis and other neural autoimmune diseases].
    Lassmann H
    Verh Dtsch Ges Pathol; 1996; 80():109-15. PubMed ID: 9064993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of neurosteroids on the pathogenesis of multiple sclerosis.
    Leitner H
    Med Hypotheses; 2010 Aug; 75(2):229-34. PubMed ID: 20227191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiology of multiple sclerosis.
    Korn T
    J Neurol; 2008 Dec; 255 Suppl 6():2-6. PubMed ID: 19300953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelin Basic Protein Citrullination in Multiple Sclerosis: A Potential Therapeutic Target for the Pathology.
    Yang L; Tan D; Piao H
    Neurochem Res; 2016 Aug; 41(8):1845-56. PubMed ID: 27097548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.